Keyphrases
Genetic Modification
100%
Phase II Study
100%
DNA Damage Repair
100%
Solid Cancer
100%
DNA Damage Response
100%
Nivolumab
100%
DNA Repair Genes
66%
DNA Damage Response Genes
66%
Targeted Sequencing
50%
Programmed Death-ligand 1 (PD-L1)
50%
Gene mutation
33%
Immune Regulation
33%
Phase II Trial
33%
Cancer Types
33%
Microsatellite Instability-high (MSI-H)
33%
Objective Response Rate
33%
Tumor mutation Burden
33%
Best Overall Response
33%
Blood Tumor mutational Burden
33%
Colorectal Cancer
16%
Antitumor Efficacy
16%
Signaling Pathway
16%
Sequence Data
16%
CD8+ T Cells
16%
Median Progression-free Survival
16%
Partial Response
16%
Progression-free Survival
16%
Overall Survival
16%
Prostate
16%
Disease Progression
16%
Non-responders
16%
Epithelial-mesenchymal Transition
16%
Discriminatory Power
16%
Common Cancers
16%
Disease Control Rate
16%
Signaling Pathway Activation
16%
Ki-67
16%
Predictive Biomarker
16%
Trial Registration
16%
Genomic Instability
16%
Aberrations
16%
RNA-seq Analysis
16%
Treatment-related Adverse Events
16%
Treatment Stage
16%
Antibody Targeting
16%
Early Progression
16%
Response Evaluation Criteria in Solid Tumors (RECIST)
16%
Biliary Tract Cancer
16%
Interleukin Signalling
16%
Medicine and Dentistry
Gene Mutation
100%
Malignant Neoplasm
100%
DNA Repair
100%
DNA Damage Response
100%
Nivolumab
100%
Tumor Mutation Burden
66%
Signal Transduction
33%
Gene Repair
33%
Progression Free Survival
33%
Immunity
33%
Phase II Trials
33%
Microsatellite Instability
33%
Biological Marker
16%
Disease
16%
Cytotoxic T-Cell
16%
Arm
16%
Adverse Event
16%
Overall Survival
16%
Cytokine
16%
Disease Exacerbation
16%
Mesenchymal-Epithelial Transition
16%
Colorectal Carcinoma
16%
Cancer Types
16%
RNA Sequence
16%
Biliary Tract Cancer
16%
Programmed Death-Ligand 1
16%
Programmed Death 1 Ligand 1
16%
Programmed Death 1 Receptor
16%
Immunology and Microbiology
Gene Mutation
100%
DNA Repair
100%
DNA Damage Response
100%
Nivolumab
100%
Signal Transduction
33%
Immunity
33%
Progression Free Survival
33%
Microsatellite Instability
33%
Immunology
33%
Cytokine
16%
Cytotoxic T-Cell
16%
Overall Survival
16%
Epithelial Mesenchymal Transition
16%
RNA Sequence
16%
Arm
16%
Interleukin
16%
Programmed Death 1 Ligand 1
16%
Programmed Death 1 Receptor
16%
Programmed Death-Ligand 1
16%
Hepatobiliary System
16%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Nivolumab
100%
Neoplasm
66%
Progression Free Survival
33%
Phase II Trials
33%
Adverse Event
16%
Disease
16%
Cytokine
16%
Biological Marker
16%
Overall Survival
16%
CD8 Antigen
16%
Disease Exacerbation
16%
Colorectal Carcinoma
16%
Biliary Tract Cancer
16%
RNA-Sequencing
16%
Programmed Death 1 Receptor
16%
Programmed Death 1 Ligand 1
16%